Patent Application
20230414499
The present application claims the priority of Chinese patent application 2020111451096 filed on Oct. 23, 2020. The contents of the Chinese patent application are incorporated herein by reference in their entirety.
The present disclosure relates to a sublingual film of Rasagiline or a pharmaceutically acceptable salt thereof, and a preparation method therefor and a use thereof.
Parkinson's disease (PD), the second most common neurodegenerative disease, mostly occurs in people over the age of 40, and 2-3% of the elderly over the age of 65 are afflicted by this disease. Symptoms are different for each Parkinson's patient, but the most common symptoms are movement disorders and stiffness of skeletal muscles, tremors, slowness of movement, poor balance and gait disturbance. In addition, it is often accompanied by depression, sleep disturbance, dizziness, dementia, speech impairment, respiratory system disease and dysphagia, and the symptoms will worsen year by year, and even lead to death.
Currently, the drugs for treating Parkinson's disease mainly include Levodopa, DA receptor agonists, MAO-B inhibitors, COMT inhibitors, anticholinergic agents, etc., wherein the most common one is Levodopa. Although Levodopa can quickly improve Parkinson's symptoms and has irreplaceable advantages, its advantage is merely in the initial few years of treatment, and the clinical effect will be significantly weakened after long-term use, and there are serious side effects, including symptoms like movement disorders, motor fluctuations (commonly known as the “on-off phenomenons”), and mental confusions, etc.
Rasagiline mesylate is a potent, selective and irreversible MAO-B inhibitor used in the treatment of Parkinson's disease, Alzheimer's disease and a variety of other disorders by inhibiting MAO in the brain. Metabolism of Rasagiline does not produce Amphetamine and does not cause unwanted sympathomimetic effects. Compared with Levodopa, Rasagiline has better safety and can be used alone for the treatment of patients with early Parkinson's disease. Currently, the marketed formulation of Rasagiline mesylate is an ordinary tablet, with the product name AZILECT, which was first launched in Israel in March 2005, in the UK in June, in Ireland in September, in the United States in 2006, and officially launched in China in 2017. The specifications are 0.5 mg and 1 mg (calculated as Rasagiline). The formulation patents on Rasagiline and pharmaceutically acceptable salts thereof are all oral administration formulations, such as Rasagiline orally disintegrating composition (CN101098685A), a Rasagiline formulation and a preparation method therefor (CN103315983A), a Rasagiline tablet (CN105496979A), a Rasagiline tablet and a preparation method therefor (CN107753446A), Rasagiline oral solid formulations (CN1911211A), orally disintegrating tablets of Rasagiline or pharmaceutically acceptable salts thereof and preparation methods therefor (CN101874790A), Rasagiline soft gelatin capsules (EP2285214B1), Rasagiline formulations and processes for their preparation (U.S. Pat. No. 7,619,117B1), Rasagiline formulations (WO2010111264A2).
After oral administration, Rasagiline mesylate is affected by the first-pass effect of the liver, and bioavailability thereof is low, about 36%. Moreover, the main risk source of Rasagiline in use is high blood pressure, which is often called the “cheese effect”. (Simpson. G. M. and White K., “Tyramine studies and the safety of MAOI drugs”, The Journal of Clinical Psychiatry, 1 Jul. 1984, 45(7 Pt 2):59-61). This effect is caused by the inhibition of peripheral MAO, which is found in high concentrations in the stomach. Orally taken Rasagiline is absorbed through the gastrointestinal tract, and patients on a high-tyramine diet are at risk of raising blood pressure at any dose (FDA: AZILECT® (Rasagiline) Tablets: Label). In addition, Parkinson's patients are usually accompanied by gastrointestinal motility disorders, mainly manifested as dysphagia, gastric emptying disorders and constipation (Wolfgang, H. Jost. “Gastrointestinal motility problems in patients with Parkinson's disease” Drugs&Aging, 10, pages 249-258 (1997)), which prolongs the time to inhibit peripheral MAO, and then aggravates the “cheese effect”.
Chinese patent application CN200910191252.6 discloses a stable Rasagiline composition, and its Example 11 discloses a film that is attached to the oral mucosa, but the film prepared thereof has poor stability, and the impurity content is as high as 2.6 to 15.33% after stored at 60° C. for 10 days.
The technical problem to be solved by the present disclosure is to overcome the defect of poor stability of Rasagiline formulations in the prior art, and to provide a sublingual film of Rasagiline or a pharmaceutically acceptable salt thereof, and a preparation method therefor and a use thereof. In the present disclosure, a drug is made into a sublingual film that is convenient for administration and stable in quality, without the need to be taken with water. The film melts swiftly, and the drug is quickly dissolved from the formulation, and the drug is absorbed through the oral mucosa, which can not only avoid the first-pass effect, but also improve bioavailability; it can also avoid the “cheese effect” caused by the inhibition of peripheral MAO in the stomach and reduce side effects.
Rasagiline is easily oxidized, unstable under acidic and alkaline conditions, and easily soluble in water, with a small dose (less than 1 mg) and a large relative amount of excipients. Therefore, the stability of the drug is greatly affected by the excipients. The inventors found that a variety of excipients are prone to interact with Rasagiline, resulting in a significant increase in the content of oxidized impurities, and the addition of antioxidants still cannot effectively solve the stability problem. In the prescription of the sublingual film prepared by Rasagiline or a pharmaceutical salt thereof, the inventor accidentally discovered through creative labor that a certain amount of one or more of maltodextrin, hydroxypropyl-β-cyclodextrin, glucosyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin which cooperates with other components in the prescription may effectively improve the stability of the film and effectively enhance the stability of the drug during long-term placement.
The present disclosure solves the above technical problem through the following technical solution.
The present disclosure provides a sublingual film of Rasagiline or a pharmaceutically acceptable salt thereof, which comprises the following prescription components:
In the present disclosure, the Rasagiline or the pharmaceutically acceptable salt thereof is preferably Rasagiline mesylate.
In the present disclosure, the polymer film-forming material can be a conventional water-soluble polymer material that can be used for film formation in the art, such as one or more of hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), hydroxypropyl cellulose (HPC), sodium carboxymethylcellulose (CMC-Na), polyvinylpyrrolidone (PVP), polyethylene oxide (PEO), sodium alginate, pullulan, Bletilla gum, corn starch and carrageenan, preferably one or more of hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), hydroxypropyl cellulose (HPC), sodium carboxymethylcellulose (CMC-Na), sodium alginate, pullulan and corn starch, such as a mixture of hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA), a mixture of hydroxypropyl cellulose (HPC) and sodium carboxymethylcellulose (CMC-Na), a mixture of polyvinyl alcohol (PVA) and corn starch, a mixture of pullulan and polyvinyl alcohol (PVP), or a mixture of hydroxypropyl methylcellulose (HPMC) and sodium alginate.
When the polymer film-forming material is the mixture of hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA), the mass ratio of hydroxypropyl methylcellulose (HPMC) to polyvinyl alcohol (PVA) can be (27.5 to 45):(22.5 to 40), such as 45:40, 42.5:37.5, 37.5:32.5, 32.5:27.5 or 27.5:22.5.
When the polymer film-forming material is the mixture of hydroxypropyl cellulose (HPC) and sodium carboxymethylcellulose (CMC-Na), the mass ratio of hydroxypropyl cellulose (HPC) to sodium carboxymethylcellulose (CMC-Na) can be 40:(25 to 35), such as 40:30.
When the polymer film-forming material is the mixture of polyvinyl alcohol (PVA) and corn starch, the mass ratio of polyvinyl alcohol (PVA) to corn starch can be 30:(25 to 35), such as 30:30.
When the polymer film-forming material is the mixture of pullulan and polyvinyl alcohol (PVP), the mass ratio of pullulan to polyvinyl alcohol (PVP) can be 20:(15 to 25), such as 20:20.
When the polymer film-forming material is the mixture of hydroxypropyl methylcellulose (HPMC) and sodium alginate, the mass ratio of hydroxypropyl methylcellulose (HPMC) to sodium alginate can be 20:(5 to 15), such as 20:10.
In the present disclosure, the dextrin is preferably maltodextrin, hydroxypropyl-β-cyclodextrin, glucosyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin, a mixture of maltodextrin and glucosyl-β-cyclodextrin, or a mixture of maltodextrin and hydroxypropyl-β-cyclodextrin.
When the dextrin is the mixture of maltodextrin and glucosyl-β-cyclodextrin, the mass ratio of maltodextrin to glucosyl-β-cyclodextrin is preferably 1:(0.8 to 1.2), such as 1:1.
When the dextrin is the mixture of maltodextrin and hydroxypropyl-β-cyclodextrin, the mass ratio of maltodextrin to hydroxypropyl-β-cyclodextrin is preferably 1:(0.8 to 1.2), such as 1:1.
In the present disclosure, the other excipients can be conventional in the art, preferably comprising one or more of an antioxidant, a disintegrant, a plasticizer, a colorant and an essence.
Where the disintegrant can be sodium carboxymethyl starch CMS-Na. The amount of the disintegrant in use can be 3 to 7%, such as 5%, and the percentage is the mass percentage relative to the total components of the prescription of the sublingual film of Rasagiline or the pharmaceutically acceptable salt thereof.
Where the plasticizer can be PEG400. The amount of the plasticizer in use can be 7 to 11%, such as 9%, and the percentage is the mass percentage relative to the total components of the prescription of the sublingual film of Rasagiline or the pharmaceutically acceptable salt thereof.
Where the colorant can be titanium dioxide. The amount of the colorant in use can be 2 to 6%, such as 4%, and the percentage is the mass percentage relative to the total components of the prescription of the sublingual film of Rasagiline or the pharmaceutically acceptable salt thereof.
Where the essence can be one or more strawberry essence, grape essence and sweet orange essence. The amount of the essence in use can be 1% or 3%, and the percentage is the mass percentage relative to the total components of the prescription of the sublingual film of Rasagiline or the pharmaceutically acceptable salt thereof.
In the present disclosure, the other excipients can also comprise a sweetener. The sweetener can be conventional in the art, preferably comprising one or more of xylitol, maltitol, steviol glycoside, sodium saccharin, aspartame, acesulfame and sodium cyclamate, more preferably one or more of xylitol, maltitol, aspartame, sodium cyclamate and steviol glycoside, such as xylitol, maltitol, aspartame, sodium cyclamate or steviol glycoside.
Where the amount of the sweetener in use can be conventional in the art, which can be 1%, 4%, 5%, 10% or 30%, preferably 3% to 30%, more preferably 5 to 20%; and the percentage is the mass percentage of the sweetener relative to the total components of the prescription of the sublingual film of Rasagiline or the pharmaceutically acceptable salt thereof.
In the present disclosure, the amount of Rasagiline or the pharmaceutical salt thereof in use can be 1%, 5%, 8%, 10% or 15%, preferably 1 to 8%.
In the present disclosure, the amount of polymer film-forming material in use can be 30%, 40%, 50%, 60%, 70%, 80% or 85%, preferably 40 to 60%. If the amount of the polymer film-forming material is lower than 30%, the film-forming property is not good, and the strength and toughness of the film may not meet the needs of use; if the amount of the polymer film-forming material is higher than 85%, the proportion of other excipients is too small, and the stability, taste and other aspects of the sublingual film of Rasagiline or the pharmaceutically acceptable salt thereof cannot meet the requirements.
In the present disclosure, the amount of dextrin in use can be 5%, 10%, 20%, 25%, 30% or 40%, preferably 10 to 30%. If the amount of dextrin is lower than 5%, the stability of the sublingual film of Rasagiline or the pharmaceutically acceptable salt thereof cannot be significantly improved; if the amount of dextrin is higher than 40%, the film is brittle and easily broken.
In the present disclosure, the amount of the other excipients in use is preferably 2 to 20%, such as 9%, 12%, 15% or 20%.
The present disclosure also provides a preparation method for the sublingual film of Rasagiline or the pharmaceutically acceptable salt thereof, which comprises the following process: coating a slurry to prepare a film;
In the present disclosure, the slurry can be prepared by conventional methods in the art, preferably by the following method: adding prescription components other than the polymer film-forming material to the aqueous slurry containing the polymer film-forming material, and mixing evenly.
Where, in the aqueous slurry containing the polymer film-forming material, the mass concentration of the polymer film-forming material is preferably 10% to 40%, more preferably 13% to 30%.
In the present disclosure, the amount of water used in the slurry can be conventional in the art, generally based on the amount of water that can be made into a solution with a certain viscosity and good fluidity.
In the present disclosure, the slurry is generally uniform. Before the slurry is coated to prepare the film, the slurry is generally left to stand for defoaming.
In the present disclosure, the method of coating to prepare the film can be conventional in the art, for example, a conventional film coating machine in the art can be used for coating, followed by drying and cutting.
Where, in the coating to prepare the film process, the thickness of the coating film can be 0.3 to 0.5 mm, such as 0.4 mm.
Where the drying temperature can be 80 to 95° C.
Where, in the coating to prepare the film process, the film coating speed can be 40 to 150 cm/min, such as 50 cm/min.
Where the specification of the cut film can be selected according to actual needs.
The present disclosure also provides a use of the sublingual film of Rasagiline or the pharmaceutically acceptable salt thereof in the manufacture of a drug for treating diseases related to Parkinson's disease, Alzheimer's disease.
The above preferred conditions can be combined arbitrarily to obtain preferred embodiments of the present disclosure by common knowledge in the art.
The reagents and raw materials used in the present disclosure are all commercially available.
The positive and progressive effects of the present disclosure are:
The present disclosure will be further described below with reference to examples, but the present disclosure is not therefore limited to the scope of the examples. Experimental methods without specific conditions in the following examples are selected according to conventional methods and conditions, or according to the commercial specification.
The raw materials and excipients used in the examples and comparative examples are conventional and commercially available.
The stability investigation, compatibility experiment, and dissolution curve test and the like in the effect examples are all carried out according to the experimental conditions and test methods specified in Pharmacopoeia.
The components and doses of Prescriptions 1 to 5 and Comparative Prescriptions are shown in Table 1.
Preparation Processes:
It can be seen from Table 1 that (1) the physical properties of the films of Prescriptions 1 to 3 of the present disclosure are better in strength and toughness than those of the films of Prescriptions 4 to 5. (2) Although the physical properties of the films of Prescriptions 4 to 5 of the present disclosure are relatively inferior to those of the Comparative Prescriptions, it can be seen from the Effect Example 4 that the Comparative Prescription has poor high-temperature stability and is unqualified. In particular, after being placed at 60° C. for 5 days, the content of related substances in the Comparative Prescriptions is as high as 1.33%, which is much higher than that of Prescriptions 1 to 5 of the present disclosure; after being placed at 60° C. for 10 days, the content of related substances in the Comparative Prescriptions is as high as 2.35%, which is much higher than that of Prescriptions 1 to 5 of the present disclosure.
The prescription of Example 2 is as shown in Table 2.
Preparation Processes:
The prescription of Example 3 is as shown in Table 3.
Preparation Processes:
The prescription of Example 4 is as shown in Table 4.
Preparation Processes:
The prescription of Example 5 is as shown in Table 5.
Preparation Processes:
The maltodextrin in the prescription of Example 3 was replaced with PVA, and the other processes of the prescription were unchanged.
The sulfobutyl-β-cyclodextrin in the prescription of Example 4 was replaced with pullulan, and the other processes of the prescription were unchanged.
After the excipients such as polymer film-forming materials and the drug were mixed in a certain proportion, purified water was added to grind evenly. The film was coated, dried, and placed at 60° C. for 10 days. The sample was taken on the 5th and 10th days to investigate the variation of related substances. The results are shown in Table 6.
As shown in Table 6, when HPMC and PVA film-forming materials are used alone, or when HPMC is compounded with EDTA, sodium pyrosulfate, ascorbic acid, and sodium bisulfite and many other conventional stabilizers, the total impurity content is much higher than when HPMC is compounded with “maltodextrin or hydroxypropyl-β-cyclodextrin”.
Other excipients and the drug were mixed in a certain proportion, followed by being placed at 60° C. for 10 days. The sample was taken on the 5th and 10th days to investigate the variation of related substances. The results are shown in Table 7.
The results in Tables 6 to 7 show that the compatibility stability of Rasagiline mesylate and various excipients is poor, and there is still no improvement after adding various conventional stabilizers, but the stability is significantly enhanced after adding dextrin.
6 films each in Prescription 1 of Example 1 and in Examples 2 to 5 (specification: 0.5 mg, i.e., each film contains 0.5 mg of Rasagiline) were taken, according to the dissolution test method (the second method of the general rule 0931 in the Chinese Pharmacopoeia (2015 edition, volume IV)), with 500 mL of phosphate buffered saline of pH 6.8 as a solvent and 50 rpm of the rotating speed, according to the method. After 1, 2, 3, 5, 10 and 15 min, 1 mL of the each solution was taken to filter, and 20 μL of the continued filtrate was precisely measured and tested according to high-performance liquid chromatography; the dissolution amount at different times was calculated. The dissolution curve is shown in
The result of
Intravenous injection: 4 healthy Beagle dogs, half male and half female, were respectively intravenously administered 4 mL of Rasagiline mesylate solution (the solvent was water) (0.5 mg/mL, calculated as Rasagiline), i.e., the administration dose was 2 mg.
Sublingual film and intragastric administration: A two-period double crossover test was adopted, and the washout period was 1 week. 4 healthy Beagle dogs, half male and half female, were randomly divided into two groups, respectively sublingually administered the sublingual film of Rasagiline mesylate (Example 3) and intragastrically administered Rasagiline mesylate solution, and the administration dose was 2 mg.
The dogs were fasted for 16 hours before administration and had free access to water. After 4 hours of administration, the dogs had free access to water, and food was administered. 2 mL of blood was collected from the forelimb or hindlimb vein before administration (0 h) and 0.033 h, 0.083 h, 0.167 h, 0.25 h, 0.333 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h after administration, and placed in heparin sodium anticoagulation tubes. The collected blood samples were centrifuged immediately (1006×g, 10 min), separated to obtain the plasma and stored at −20° C. Using Selegiline hydrochloride as the internal standard and processing by using acetonitrile protein precipitation method, the plasma concentration of Rasagiline in the sample was determined by LC-MS/MS, and the average drug-time curve was drawn (
The result in
The films of Comparative Prescription and Prescriptions 1 to 5 in Example 1 (specification: 0.5 mg) were taken, and the outer packaging was removed, and a high temperature test was conducted to investigate the stability of the sample.
The film was placed in a culture dish at 60° C. for 10 days, and samples were taken on the 5th and 10th days to test the related substances of Rasagiline in the film. The test results show that the proportion of hydroxypropyl-β-cyclodextrin is in the range of 5 to 40%, and the stability of the drug under high temperature environment is enhanced with the increase of the amount of hydroxypropyl-β-cyclodextrin. However, with the increase of the amount of hydroxypropyl-β-cyclodextrin, the amount of film-forming materials needs to be reduced accordingly. The strength of the film gradually decreases, and the toughness gradually deteriorates. The results are shown in Table 8.
Stability Investigation of Different Prescription Samples
The films in Comparative Example 1, Comparative Example 2 and Examples 2 to 5 (specification: 0.5 mg) were taken, and the outer packaging was removed, and a high temperature test was conducted to investigate the stability of the sample.
The film was placed in a culture dish at 60° C. for 10 days, and samples were taken on the 5th and 10th days to test the content, related substances and dissolution rate of Rasagiline in the film (see Effect Example 2 for the dissolution method). The test result shows that during the investigation period, the related substances of the sublingual film of Rasagiline mesylate produced in Comparative Example 1 and Comparative Example 2 increase significantly, and the results are shown in Tables 9 to 10. The sublingual films of Rasagiline mesylate prepared in the present disclosure, i.e., Examples 2 to 5, have no obvious change in each index and have stable product quality, and the results are shown in Tables 11 to 14.
The results in Tables 9 to 14 show that due to the synergistic effect of each component, the total impurity of the sublingual film of Rasagiline mesylate of the present disclosure does not exceed 1% after storing at a high temperature of 60° C. for 10 days, and the stability increases with the increase of the proportion of dextrin. Compared with Comparative Example 1 and Comparative Example 2 without dextrin added, after being placed at high temperature, there is no obvious variation in the dissolution rate and content, and the increase of related substances is obviously reduced, and the stability is obviously enhanced.
In the present disclosure, the oral film of Rasagiline does not need water or other liquids when taken. The packaging bag is torn open with dry hands, and the film is taken out, and placed in the oral cavity until completely dissolved. This product should not be folded, chewed or swallowed. Feeding or drinking should be avoided within 10 min after dosing.
Stability Investigation of Samples with Different Water Content
Stability Investigation of Samples with Different Water Content
Films with different water content were prepared according to the prescription and preparation method of Example 3 (column 2 in the table below), packaged and sealed in PET/A1/PE bags, and placed at 60° C. for 10 days. The samples were taken on the 5th and 10th days to test the related substances in the film. The test results are shown in Table 15.
The results in Table 15 show that water content has an effect on the stability of the sublingual film of Rasagiline mesylate of the present disclosure, and as the water content increases, the stability of the sublingual film of the present disclosure is enhanced.
Although the specific implementations of the present disclosure have been described above, those skilled in the art should understand that these are only examples, and various changes or modifications can be made to these implementations without departing from the principle and essence of the present disclosure. Accordingly, the protection scope of the present disclosure is defined by the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202011145109.6 | Oct 2020 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2021/083192 | 3/26/2021 | WO |
